Governors Lane LP Takes Position in Danaher Corporation $DHR

Governors Lane LP purchased a new stake in Danaher Corporation (NYSE:DHR) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 43,534 shares of the conglomerate’s stock, valued at approximately $8,292,000.

Several other large investors have also recently bought and sold shares of the business. Ramsay Stattman Vela & Price Inc. boosted its position in shares of Danaher by 3.8% during the 2nd quarter. Ramsay Stattman Vela & Price Inc. now owns 62,105 shares of the conglomerate’s stock worth $11,830,000 after purchasing an additional 2,288 shares in the last quarter. Arizona State Retirement System increased its holdings in shares of Danaher by 1.4% in the 2nd quarter. Arizona State Retirement System now owns 176,736 shares of the conglomerate’s stock valued at $33,665,000 after purchasing an additional 2,519 shares in the last quarter. Lipe & Dalton lifted its stake in shares of Danaher by 4.4% in the second quarter. Lipe & Dalton now owns 21,358 shares of the conglomerate’s stock valued at $4,068,000 after purchasing an additional 900 shares during the period. Empirical Finance LLC lifted its stake in shares of Danaher by 3.3% in the second quarter. Empirical Finance LLC now owns 22,703 shares of the conglomerate’s stock valued at $4,324,000 after purchasing an additional 726 shares during the period. Finally, Nykredit A S purchased a new stake in Danaher during the second quarter worth about $30,377,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on DHR. DZ Bank started coverage on shares of Danaher in a research report on Wednesday, June 3rd. They set a “buy” rating and a $210.00 target price on the stock. HSBC decreased their price target on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Evercore reaffirmed an “outperform” rating and issued a $230.00 price objective on shares of Danaher in a research note on Monday, July 6th. Weiss Ratings raised Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, July 15th. Finally, Citigroup started coverage on Danaher in a research report on Tuesday, May 26th. They set a “buy” rating and a $230.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $228.91.

Danaher Stock Down 1.2%

Shares of NYSE DHR opened at $205.23 on Wednesday. The firm’s 50-day moving average is $202.33 and its two-hundred day moving average is $192.13. The company has a market capitalization of $144.28 billion, a PE ratio of 36.45, a price-to-earnings-growth ratio of 2.59 and a beta of 0.78. Danaher Corporation has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. During the same period last year, the company posted $0.77 EPS. The company’s revenue was up 5.5% on a year-over-year basis. Equities analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

About Danaher

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.